Literature DB >> 21841788

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.

Daniela Ungureanu1, Jinhua Wu, Tuija Pekkala, Yashavanthi Niranjan, Clifford Young, Ole N Jensen, Chong-Feng Xu, Thomas A Neubert, Radek C Skoda, Stevan R Hubbard, Olli Silvennoinen.   

Abstract

Human JAK2 tyrosine kinase mediates signaling through numerous cytokine receptors. The JAK2 JH2 domain functions as a negative regulator and is presumed to be a catalytically inactive pseudokinase, but the mechanism(s) for its inhibition of JAK2 remains unknown. Mutations in JH2 lead to increased JAK2 activity, contributing to myeloproliferative neoplasms (MPNs). Here we show that JH2 is a dual-specificity protein kinase that phosphorylates two negative regulatory sites in JAK2: Ser523 and Tyr570. Inactivation of JH2 catalytic activity increased JAK2 basal activity and downstream signaling. Notably, different MPN mutations abrogated JH2 activity in cells, and in MPN (V617F) patient cells phosphorylation of Tyr570 was reduced, suggesting that loss of JH2 activity contributes to the pathogenesis of MPNs. These results identify the catalytic activity of JH2 as a previously unrecognized mechanism to control basal activity and signaling of JAK2.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841788      PMCID: PMC4504201          DOI: 10.1038/nsmb.2099

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  39 in total

Review 1.  Signaling by type I and II cytokine receptors: ten years after.

Authors:  M Gadina; D Hilton; J A Johnston; A Morinobu; A Lighvani; Y J Zhou; R Visconti; J J O'Shea
Journal:  Curr Opin Immunol       Date:  2001-06       Impact factor: 7.486

2.  Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Authors:  Pipsa Saharinen; Mauno Vihinen; Olli Silvennoinen
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

3.  In-gel digestion for mass spectrometric characterization of proteins and proteomes.

Authors:  Andrej Shevchenko; Henrik Tomas; Jan Havlis; Jesper V Olsen; Matthias Mann
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity.

Authors:  Lawrence S Argetsinger; Jeanne A Stuckey; Scott A Robertson; Rositsa I Koleva; Joel M Cline; Jarrod A Marto; Martin G Myers; Christin Carter-Su
Journal:  Mol Endocrinol       Date:  2010-03-19

5.  Highly selective enrichment of phosphorylated peptides using titanium dioxide.

Authors:  Tine E Thingholm; Thomas J D Jørgensen; Ole N Jensen; Martin R Larsen
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

6.  Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling.

Authors:  Edward P Feener; Felicia Rosario; Sarah L Dunn; Zlatina Stancheva; Martin G Myers
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

7.  Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling.

Authors:  Ryoko Ishida-Takahashi; Felicia Rosario; Yusong Gong; Keely Kopp; Zlatina Stancheva; Xiaohong Chen; Edward P Feener; Martin G Myers
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 8.  Pseudokinases-remnants of evolution or key allosteric regulators?

Authors:  Elton Zeqiraj; Daan M F van Aalten
Journal:  Curr Opin Struct Biol       Date:  2010-11-10       Impact factor: 6.809

Review 9.  Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Authors:  Claude Haan; Iris Behrmann; Serge Haan
Journal:  J Cell Mol Med       Date:  2010-01-28       Impact factor: 5.310

10.  Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.

Authors:  Elton Zeqiraj; Beatrice Maria Filippi; Maria Deak; Dario R Alessi; Daan M F van Aalten
Journal:  Science       Date:  2009-11-05       Impact factor: 47.728

View more
  94 in total

Review 1.  PseudoGTPase domains in p190RhoGAP proteins: a mini-review.

Authors:  Amy L Stiegler; Titus J Boggon
Journal:  Biochem Soc Trans       Date:  2018-12-04       Impact factor: 5.407

Review 2.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

3.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

4.  Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).

Authors:  Xiaoshan Min; Daniela Ungureanu; Sarah Maxwell; Henrik Hammarén; Steve Thibault; Ellin-Kristina Hillert; Merrill Ayres; Brad Greenfield; John Eksterowicz; Chris Gabel; Nigel Walker; Olli Silvennoinen; Zhulun Wang
Journal:  J Biol Chem       Date:  2015-09-10       Impact factor: 5.157

Review 5.  JAK/STAT pathway dysregulation in tumors: a Drosophila perspective.

Authors:  Marc Amoyel; Abigail M Anderson; Erika A Bach
Journal:  Semin Cell Dev Biol       Date:  2014-03-28       Impact factor: 7.727

Review 6.  Kinase signaling and targeted therapy for primary myelofibrosis.

Authors:  Qiong Yang; John D Crispino; Qiang Jeremy Wen
Journal:  Exp Hematol       Date:  2016-12-30       Impact factor: 3.084

7.  CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Authors:  Sara C Meyer; Matthew D Keller; Sophia Chiu; Priya Koppikar; Olga A Guryanova; Franck Rapaport; Ke Xu; Katia Manova; Dmitry Pankov; Richard J O'Reilly; Maria Kleppe; Anna Sophia McKenney; Alan H Shih; Kaitlyn Shank; Jihae Ahn; Eftymia Papalexi; Barbara Spitzer; Nick Socci; Agnes Viale; Emeline Mandon; Nicolas Ebel; Rita Andraos; Joëlle Rubert; Ernesta Dammassa; Vincent Romanet; Arno Dölemeyer; Michael Zender; Melanie Heinlein; Raajit Rampal; Rona Singer Weinberg; Ronald Hoffman; William R Sellers; Francesco Hofmann; Masato Murakami; Fabienne Baffert; Christoph Gaul; Thomas Radimerski; Ross L Levine
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

8.  JH2 is active!

Authors:  Kim Baumann
Journal:  Nat Rev Mol Cell Biol       Date:  2011-08-23       Impact factor: 94.444

Review 9.  Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Authors:  Sara C Meyer; Ross L Levine
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

10.  JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs.

Authors:  Friederike Pastore; Aishwarya Krishnan; Henrik M Hammarén; Olli Silvennoinen; Benedict Yan; Ross L Levine
Journal:  Blood Adv       Date:  2020-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.